Trial Profile
Investigator-initiated observational cohort study aimed to assess the cardiovascular safety of amphetamines, methylphenidate, and atomoxetine, commonly-used medications for the treatment of patients with attention-deficit hyperactivity disorder
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Feb 2020
Price :
$35
*
At a glance
- Drugs Methylphenidate (Primary) ; Amphetamines; Atomoxetine
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- 26 Feb 2020 Status changed from recruiting to completed.
- 27 Jul 2010 New trial record